Stockreport
Bleeding Disorders Treatment Market Size to Hit USD 35.17 Billion by 2032 – SNS Insider [Yahoo! Finance]
Last biogen inc. earnings: 4/22 07:12 am
Check Earnings Report
US:NASDAQ Investor Relations: biogen.com/en_us/investors.html
Pune, March 04, 2025 (GLOBE NEWSWIRE) -- Bleeding Disorders Treatment Market Size & Growth Analysis: “According to SNS Insider, The Bleeding Disorders Treatment Market Size was valued at USD 16.35 billion in 2023 and is expected to attain a valuation of USD 35.17 billion by 2032, at a CAGR of 8.91% between 2024 to 2032.” The Bleeding Disorders Treatment Market is witnessing substantial growth, fueled by the increasing prevalence of bleeding disorders such as hemophilia, von Willebrand disease, and other rare coagulation disorders, alongside advancements in treatment options and supportive government initiatives. Get a Sample Report of Bleeding Disorders Treatment Market@ https://www.snsinsider.com/sample-request/4973 Market analysis The increasing diagnosis of bleeding disorders, better treatment options, and supportive government policies are driving the expansion. According to the World Federation of Hemophilia (WFH), over 1.1 million people worldwide suffer from hemophil
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | BIIB | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BIIB alerts
BIIB alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIIB alerts
High impacting Biogen Inc. news events
Weekly update
A roundup of the hottest topics
BIIB
NEWS
NEWS
- Biogen Inc. (NASDAQ: BIIB) was downgraded by analysts at Argus from a "buy" rating to a "hold" rating.[MarketBeat]
- Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease[GlobeNewswire]
- Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. [Yahoo! Finance][Yahoo! Finance]
- Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square[GlobeNewswire]
- There's a $1 trillion opportunity brewing in the stock market — and it's got nothing to do with AI [Business Insider][Business Insider]
- More
BIIB
SEC Filings
SEC Filings
- 4/3/25 - Form 4
- 3/10/25 - Form 4
- 3/10/25 - Form 3
- BIIB's page on the SEC website
- More